Insulet's wearable insulin pumps will be integrated with blood glucose monitors from both companies.
News & Analysis: Insulet
What should investors think of this promising diabetes stock?
The company will replace its Omnipod DASH Personal Diabetes Managers next month to correct a software problem.
Shares of the insulin pump maker continued their powerful performance last month.
Shares of the leader in tubeless insulin pump technology have investors pumped up.
The diabetes-management space is poised to continue to grow.
These two stocks don't appear to be slowing down anytime soon.
Investors counting on the company's dominance of the closed-loop artificial pancreas market might want to temper their expectations.
The 2010s were good to shares of this diabetes specialist, aerospace company, and backup generator maker.
Shares of the leader in tubeless insulin pump technology have gained a whopping 129% so far in 2019.